Clinical Trial Update: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety study evaluating twice-daily momelotinib in myelofibrosis populations has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Momelotinib (momelotinib)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera | Phase 1, Phase 2 | Status: COMPLETED